Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals (NASDAQ:KERX) from a sell rating to a hold rating in a report issued on Friday, December 1st.
According to Zacks, “Keryx’s loss in third-quarter 2017 was wider than expected while sales missed estimates. The FDA approval for the label expansion of Auryxia to treat adults with iron deficiency anemia (IDA) and chronic kidney disease, not on dialysis, might boost sales of the company, given that the IDA market holds great potential. With the latest approval, this drug can treat two complications of chronic kidney disease. The company also believes that the formulary additions at two major Part D providers will continue to support and drive the future growth of Aurexia. The company is also conducting few studies for further label expansion of the drug which should bode well for it. “
Other equities research analysts have also issued reports about the stock. BidaskClub raised shares of Keryx Biopharmaceuticals from a sell rating to a hold rating in a report on Wednesday, August 16th. ValuEngine lowered shares of Keryx Biopharmaceuticals from a hold rating to a sell rating in a research note on Thursday, September 21st. Finally, Stifel Nicolaus reduced their price target on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a hold rating for the company in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. Keryx Biopharmaceuticals currently has a consensus rating of Hold and a consensus price target of $7.35.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) opened at $4.64 on Friday. Keryx Biopharmaceuticals has a twelve month low of $4.33 and a twelve month high of $8.38. The company has a debt-to-equity ratio of 13.95, a quick ratio of 3.76 and a current ratio of 4.46.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $15.00 million during the quarter, compared to the consensus estimate of $18.88 million. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The business’s quarterly revenue was up 138.1% on a year-over-year basis. During the same period last year, the firm earned ($0.39) EPS. equities research analysts predict that Keryx Biopharmaceuticals will post -1.36 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Perceptive Advisors LLC purchased a new position in shares of Keryx Biopharmaceuticals during the 3rd quarter worth approximately $592,000. Engineers Gate Manager LP purchased a new position in Keryx Biopharmaceuticals in the 3rd quarter valued at approximately $102,000. Schwab Charles Investment Management Inc. boosted its position in Keryx Biopharmaceuticals by 12.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 495,896 shares of the biopharmaceutical company’s stock valued at $3,521,000 after buying an additional 54,790 shares during the period. EAM Investors LLC purchased a new position in Keryx Biopharmaceuticals in the 3rd quarter valued at approximately $1,526,000. Finally, Russell Investments Group Ltd. boosted its position in Keryx Biopharmaceuticals by 742.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 754,631 shares of the biopharmaceutical company’s stock valued at $5,358,000 after buying an additional 665,069 shares during the period. Institutional investors and hedge funds own 64.83% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Keryx Biopharmaceuticals (NASDAQ:KERX) Upgraded to Hold by Zacks Investment Research” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://ledgergazette.com/2017/12/18/keryx-biopharmaceuticals-kerx-upgraded-to-hold-at-zacks-investment-research.html.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.